Montana’s treatment board grants first approval with conditions
Montana’s treatment board required consent changes in its first approval, while the combination of clemastine and audio remains under placebo-controlled testing.
Montana’s board grants its first treatment approval with conditions
The board required the patient consent form to drop the claim that the drug’s safety in humans had already been established. This was one condition of its first treatment approval.
The board is chaired by Matt Kaeberlein. On October 31, he responded to criticism of the state law allowing sales of unapproved drugs after Phase 1 trials. This phase usually tests safety in 20 to 100 participants. Kaeberlein says completing it provides a starting point for protocol review. An independent board reviews each protocol for safety, clarity of consent, the balance of risks and benefits, and other treatment options.
The board issued its first decision on August 26, voting 5 to 0 to approve a therapy from Parley Neurotech with conditions. It combines the antihistamine clemastine with specially designed audio delivered through headphones and is intended to treat an age-related decline in understanding speech in noise. Alongside removing the safety claim, the board required the consent form to recommend that the physician assess kidney and liver function, blood tests, heart health, and fall risk.
Clemastine completed Phase 1 during its original development, while the combination of the drug and audio is still being tested against placebo. Based on the company’s assurance and a legal memorandum, the board found “reasonable grounds” to consider the Phase 1 requirement met for the combination. The board therefore required changes to the information given to patients, but its approval does not itself establish efficacy. The trial is still testing whether the treatment works.
The consequences of early sales concern Thomas Seoh, executive vice president of the Kitalys think tank. He argues that patients who can buy a drug have less incentive to enter a placebo-controlled trial, while investors may prefer revenue to a trial that could show no benefit. The report provides no evidence that this has already happened. Kaeberlein also worries that future boards could lower their standards. In its first decision, the board required specific corrections, while the approved therapy’s efficacy remains an open question.
Open the related Eternal Search page
Sources
[1] linkedin.com
[2] linkedin.com
[3] archive.legmt.gov
[4] t.me
[5] nbcmontana.com
[6] dphhs.mt.gov
[7] factcheck.org
[8] drive.google.com
This item links Matt Kaeberlein’s public profile to a specific regulatory responsibility: the board he chairs has already set conditions for experimental treatment access, while the decisive efficacy evidence is still pending.